Brinker Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Brinker Capital’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-40,952	Closed	-$292K	–	1000
2020 Q1	$292K	Sell	40,952 -2,422	-6%	-$30.2K	0.01%	783
2019 Q4	$1.04M	Sell	43,374 -566	-1%	-$15.6K	0.03%	492
2019 Q3	$1.18M	Buy	43,940 +12,620	+40%	+$354K	0.04%	435
2019 Q2	$850K	Sell	31,320 -866	-3%	-$27.2K	0.03%	534
2019 Q1	$1.12M	Buy	+32,186	New	+$929K	0.04%	417

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Brinker Capital's PTLA Position: Q2 2020 in Review

Brinker Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 40,952 shares — an estimated $292K sold.

Brinker Capital first reported a position in PTLA in Q1 2019 and held it in 5 quarters. The position peaked at $1.18M in Q3 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Brinker Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Brinker Capital sold 40,952 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $292K.
Brinker Capital first reported a position in Portola Pharmaceuticals, Inc. in Q1 2019 and held it in 5 quarters.
Brinker Capital's Portola Pharmaceuticals, Inc. position peaked at $1.18M in Q3 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.